{"title":"Semaglutide:口服GLP-1受体类似物","authors":"A. Kochar","doi":"10.54136/erwej-0101-10008","DOIUrl":null,"url":null,"abstract":"Semaglutide seems to be a promising option for early and later stages of diabetes treatment, it is a first-in-class oral GLP-1RA and has shown up to a 1.5 % reduction in HbA1c across PIONEER trials. Semaglutide could be a revolutionary option for the management of diabetes, being the most efficacious profile of oral diabetics known along with the convenience of oral administration.","PeriodicalId":312076,"journal":{"name":"Exclusive Real World Evidence Journal","volume":"86 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Semaglutide: Oral GLP-1 Receptor Analogue\",\"authors\":\"A. Kochar\",\"doi\":\"10.54136/erwej-0101-10008\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Semaglutide seems to be a promising option for early and later stages of diabetes treatment, it is a first-in-class oral GLP-1RA and has shown up to a 1.5 % reduction in HbA1c across PIONEER trials. Semaglutide could be a revolutionary option for the management of diabetes, being the most efficacious profile of oral diabetics known along with the convenience of oral administration.\",\"PeriodicalId\":312076,\"journal\":{\"name\":\"Exclusive Real World Evidence Journal\",\"volume\":\"86 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1900-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Exclusive Real World Evidence Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.54136/erwej-0101-10008\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Exclusive Real World Evidence Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.54136/erwej-0101-10008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Semaglutide seems to be a promising option for early and later stages of diabetes treatment, it is a first-in-class oral GLP-1RA and has shown up to a 1.5 % reduction in HbA1c across PIONEER trials. Semaglutide could be a revolutionary option for the management of diabetes, being the most efficacious profile of oral diabetics known along with the convenience of oral administration.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
